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First maintenance therapy for COPD in the UK between
2009 and 2012: a retrospective database analysis
David Price1, Marc Miravitlles2, Ian Pavord3, Mike Thomas4, Jadwiga Wedzicha5, John Haughney1, Katsiaryna Bichel6 and Daniel West6
Clinical guidelines recommend long-acting bronchodilators as ﬁrst maintenance therapy for chronic obstructive pulmonary disease
(COPD), with inhaled corticosteroids (ICS) reserved for patients with more severe disease and exacerbations. The aim of this analysis
was to examine real-life prescribing of ﬁrst maintenance therapy for COPD in the UK. Data were extracted from the UK Optimum
Patient Care Research Database for patients with a ﬁrst prescription for COPD maintenance therapy between 2009 and 2012 and a
diagnosis of COPD at or before the date of the ﬁrst prescription for COPD maintenance therapy. Routine clinical data including
demographics, disease history and symptoms, comorbidities, therapy, hospitalisation rate and exacerbation rate were collected and
used to characterise patients stratiﬁed by disease severity and Global Initiative for Chronic Obstructive Lung Disease (GOLD) group
(A–D). The analysis population included 2,217 individuals (55.4% male, 45.2% smokers). Long-acting muscarinic antagonists (LAMA)
as monotherapy were prescribed as ﬁrst maintenance therapy for 40.2% of patients. ICS were prescribed as ICS/long-acting
beta-agonists combination for 29.1% of patients or as monotherapy for 15.5%. ICS (alone or in combination) were prescribed to
440% of patients in each GOLD group. ICS-containing regimens were prescribed to patients with a history of pneumonia and
comorbid conditions for whom the risks of ICS therapy may outweigh the beneﬁts. The clinical reality of prescribing indicates that
ICS are often prescribed outside current guideline recommendations for many patients newly diagnosed with COPD in the UK.
Encouragingly, LAMAs are increasingly being prescribed as ﬁrst maintenance therapy for these patients.
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INTRODUCTION
Over one million individuals in the UK are currently living with
chronic obstructive pulmonary disease (COPD), with an
estimated 25,000 deaths each year from the disease.1 COPD is a
complex condition with both pulmonary and extrapulmonary
manifestations necessitating a holistic approach to the evaluation
and management of patients. In the UK, patients with COPD are
largely managed in the primary care setting.2 The National
Institute for Health and Care Excellence (NICE) guidelines for the
assessment and management of patients with COPD advocate a
multidimensional approach in agreement with recommendations
from the Global Initiative for Chronic Obstructive Lung Disease
(GOLD).3,4 Broadly, the goals of treatment are to relieve the
symptoms of breathlessness, reduce the frequency and severity of
exacerbations, improve health-related quality of life, improve
exercise capacity and slow disease progression (through smoking
cessation).
UK NICE guidelines recommend bronchodilators as initial
therapy comprising short-acting beta-agonists or short-acting
muscarinic antagonists. For those patients with stable COPD who
remain breathless despite using short-acting bronchodilators,
long-acting muscarinic antagonists (LAMAs) or long-acting
beta-agonists (LABAs) are recommended as maintenance therapy
if the forced expiratory volume over 1 s (FEV1) is ⩾ 50%, and
LABA+inhaled corticosteroid (ICS) or LAMA for those with FEV1
o50% predicted.4 These recommendations are in line with GOLD
recommendations, which suggest that inhaled ICS therapy should
be reserved as an option for those in GOLD groups C or D.3
The role of ICS in the management of patients with COPD is still
debated. These agents have not been shown to prevent disease
progression or reduce mortality in controlled clinical trials and
are generally prescribed with the aim of reducing the frequency or
severity of exacerbations.5 However, many of the inﬂammatory
processes found in individuals with COPD are of a type not
amenable to ICS therapy and it remains unclear which
patients can be expected to gain meaningful beneﬁt.6 An
additional challenge when managing patients with COPD is that
comorbidities are common and these can impact prognosis.3
Comorbid conditions may also inﬂuence treatment decisions,
particularly with respect to ICS therapy which has been shown to
increase the risk for infective comorbidities and be associated
with the presence of non-infective comorbidities.7 Given these
challenges and unanswered questions, it is perhaps unsurprising
that there are data to suggest that clinical practice does not
always reﬂect current clinical guidelines in the UK8 and other
European countries.9–12
We reported a previous evaluation of prescribing patterns in the
UK among 24,957 patients with moderate airﬂow limitation
(FEV1 ⩾ 50% to o80%) COPD, which corresponds to GOLD
stage II.13 In this large cohort of patients, around half were
receiving an ICS alone or in combination with a LABA or a LABA
and a LAMA, a treatment approach not in line with either
NICE recommendations or GOLD guidelines. To extend these
observations regarding treatment of all patients with COPD,
we evaluated treatment selection (prescribing) for patients
commencing ﬁrst maintenance therapy for COPD in the UK.
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This approach was undertaken in order to investigate
whether treatment selection for ﬁrst maintenance therapy aligns
with current local and international treatment guidelines with
respect to patient characteristics, medical history, disease severity
and the presence of comorbidities, particularly with respect to
ICS use.
RESULTS
The population for analysis comprised 2,217 individuals with
a diagnosis of COPD (conﬁrmed by a post-bronchodilator
FEV1/forced vital capacity o0.7 for 83% of patients), 55.4% of
whom were male, 45.2% were smokers and 46.9% were
ex-smokers. Figure 1 illustrates the derivation of the patient
cohort for the current analyses. The majority of patients had
received their initial diagnosis of COPD and ﬁrst major therapy for
COPD when they were aged ⩾ 60 to o75 years of age (54.0% and
53.2%, respectively; Table 1).
First maintenance therapy
The most commonly prescribed ﬁrst maintenance therapy for
COPD was a LAMA (40.2% of patients) followed by an ICS+LABA
combination (29.1% of patients). ICS monotherapy was prescribed
as ﬁrst COPD maintenance therapy for 15.5% of patients.
Figure 2 details the prescribing pattern for the ﬁrst major
therapy class by GOLD group. Among patients initially assessed as
GOLD group A or B, 385/803 (47.9%) and 226/461 (49.0%),
respectively, received an initial prescription of an ICS alone or in
combination with a bronchodilator. ICS-containing regimens were
prescribed to 440.0% of patients in each GOLD group.
Comorbidities, pneumonia history and prescribing patterns
Among the 2,217 patients newly diagnosed with COPD before or
at their ﬁrst major therapy prescription, 6.8% (n= 150) had a
history of pneumonia, 11.4% had osteoporosis (n= 252), 15.9%
had chronic kidney disease (n= 353), 17.2% had asthma (n= 381)
and 23.6% (n= 524) had diabetes (Type 1 or Type 2).
These comorbidities were apparent among those with GOLD
group A and B COPD (osteoporosis 10.5% (84/803) and 14.3%
(66/461), chronic kidney disease 14.2% (114/803) and 20.8%
(96/461) and diabetes (Type 1 and Type 2) 19.1% (153/803) and
28.9% (133/461), respectively; Figure 3). In all, 5.5% (44/803) and
5.4% (25/461) in GOLD groups A and B, respectively, had a history
of pneumonia.
An ICS was prescribed in 255/381 (67%) patients with asthma,
either as monotherapy (25%) or in combination with a
bronchodilator (42%). Among the 150 patients with a history of
pneumonia prior to the ﬁrst major therapy prescription for COPD,
76 (50.7%) were initially prescribed an ICS-containing regimen
(Figure 4). ICS-containing regimens were also prescribed as
ﬁrst maintenance therapy for 134/252 (53.2%) of those with
comorbid osteoporosis and 270/524 (51.5%) of those with
comorbid diabetes (Type 1 and Type 2).
Inclusion criteria
Exclusion criteria
Diagnostic code for COPD
and recorded spirometry data
within 5-year window of
diagnostic code
Registered at practice at
least 1 year prior to receiving
major therapy
Received first major therapy
in 2009–2012 (ICS, LABA,
LAMA or their combination)
No complete data until
2012 (n = 386,696),
no diagnostic code for
COPD (n = 450,413)
AND
no spirometry data recorded
(n = 14,292)  
Does not have 1-year
baseline/outcome data
n = 7,952 
Did not receive COPD
maintenance therapy OR
received prior to 2009
n = 7,889
COPD diagnosis after
receiving first COPD
maintenance therapy
n = 699
OPCRD
patients
n = 870,158 
COPD diagnosis
n = 18,757
Registered at practice
n = 10,805
Received major therapy in
2009–2012
n = 2,916 
COPD diagnosis prior to
receiving first COPD
maintenance therapy
n = 2,217
(Final study population)
Figure 1. Consort diagram. COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist;
LAMA, long-acting muscarinic antagonist; OPCRD, Optimum Patient Care Research Database.
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DISCUSSION
Main ﬁndings
The data presented here suggest that bronchodilator therapy is
increasingly prescribed as ﬁrst maintenance therapy for patients
newly diagnosed with COPD in the UK. However, a relevant
proportion of patients continue to receive ﬁrst maintenance
therapy that is not consistent with current recommendations with
respect to the prescription of ICS.3,4
Interpretation of ﬁndings in relation to previously published work
The results presented here for the UK are consistent with
observations in other countries including France, Italy,
Norway, Spain, Switzerland and the USA.9–12,14–17 Furthermore,
baseline demographic data in the current study are comparable to
those in similar studies, including much larger real-world
populations of patients with COPD.18,19 Of particular concern is
the observation that 15.5% of patients were prescribed an ICS
monotherapy as their ﬁrst maintenance therapy despite the lack
of data, or a licensed indication, to support the use of ICS as
monotherapy in COPD at any severity level.16
Higher-dose ICS therapy has been shown to increase the risk for
side effects, including pneumonia and fractures. However, if the
beneﬁts outweigh the associated risks, it may be in a patient’s best
interest to receive ICS therapy and this should be decided on a
patient-by-patient basis.20–22 Importantly, the inappropriate
prescribing of ICS exposes patients to the risk of the potentially
serious side effects of treatment without the counterbalance of an
evidence-based efﬁcacy beneﬁt. Our observations of an overuse of
ICS as ﬁrst maintenance therapy are consistent with a recent
cross-sectional evaluation of ICS use among patients with COPD
across 41 primary care practices in London.17 The authors found
that ICS were widely prescribed against current recommendations,
including for 38.0% of patients classed as GOLD stage I or II
according to the GOLD 2011 guidelines and 33.6% of those
classed as GOLD stage III or IV but without exacerbations.17
Moreover, 440.0% of those classed as GOLD stage IV, for whom
ICS therapy is recommended in current guidelines, were not
prescribed these agents. The results of our study conﬁrm and
extend the observations reported by White et al.17 and show that
ICS are widely and inappropriately prescribed to patients with
COPD from the time of diagnosis regardless of GOLD stage.
The reason for the apparent inappropriate prescribing of ICS as
ﬁrst-line therapy may lie, at least in part, in the discrepancy
between recommended use of ICS+LABA combinations in clinical
guidelines and the actual approved indications for these
combinations. GOLD recommend that ICS+LABA be reserved for
patients with GOLD group C or D.3 However, the licensed
indication for these combination products is for patients with
severe COPD with exacerbations. Consequently, ICS+LABA are
approved for use only in a subset of patients classed as GOLD
group C or D as the majority of these patients experience only
infrequent exacerbations.23
Implications for future research, policy and practice
Our results have shown that ICS prescribing is common even for
patients with comorbidities or a medical history of conditions
that might suggest against the use of an ICS, including a history
of pneumonia, fractures and diabetes (Type 1 and Type 2).
The implications of inappropriate ICS prescribing for patients with
pre-existing comorbidities has the potential to increase the risk
for infective comorbidities such as pneumonia5,21,24–27 and
non-infective comorbidities including fractures21,28 and worsening
glycaemic control among those with diabetes.29,30 Consequently,
patients who meet guideline criteria for ICS prescription
(GOLD group C or D with exacerbations) with regard to their
COPD should be evaluated carefully for the presence of
Table 1. Baseline demographics and disease characteristics
Variable, N (%) Total study population
(N= 2,217)
Age at initial COPD diagnosis
o60 years 497 (22.4)
⩾ 60 to o75 years 1,197 (54.0)
⩾ 75 years 523 (23.6)
Age at ﬁrst major therapy
o60 years 403 (18.2)
⩾ 60 to o75 years 1,179 (53.2)
⩾ 75 years 635 (28.6)
Time from COPD diagnosis to ﬁrst prescription
for COPD maintenance therapy, median years
(range)
0.4 (0–2.6)
Male gender 1,229 (55.4)
Smoking status
Non-smoker 174 (7.9)
Current smoker 1,002 (45.2)
Ex-smoker 1,040 (46.9)
Unknown 1 (o0.1)
GOLD COPD severity post-bronchodilator
1: FEV1 ⩾ 80% predicted 204 (11.1)
2: 50%⩽ FEV1 o80% predicted 1,038 (56.4)
3: 30%⩽ FEV1 o50% predicted 499 (27.1)
4: FEV1 o30% predicted 99 (5.4)
Unconﬁrmed COPD (FEV1/FVC o0.7) 377 (17.0)
GOLD groupa
A 803 (36.9)
B 461 (21.2)
C 516 (23.7)
D 396 (18.2)
Unknown 41 (1.8)
Moderate and severe exacerbation rateb
0 1,177 (53.1)
1 598 (27.0)
2 280 (12.6)
⩾ 3 162 (7.3)
First COPD maintenance prescription
ICS 344 (15.5)
ICS+LABA 646 (29.1)
ICS+LAMA 12 (0.5)
ICS+LABA+LAMA 129 (5.8)
LAMA 891 (40.2)
LABA 186 (8.4)
LAMA+LABA 9 (0.4)
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory
volume over 1 s; FVC, forced vital capacity; GOLD, Global Initiative for
Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LABA, long-
acting beta-agonist; LAMA, long-acting muscarinic antagonist; MRC,
Medical Research Council.
aGOLD group (A–D): A is least severe and D is most severe COPD. GOLD
group determined according to MRC score. Both routine medical practice
recorded and patient questionnaire MRC scores were used with the most
recent score taking precedence. The category ‘Unknown’ was assigned to
patients with no MRC score available.
b1 year prior to/at ﬁrst COPD maintenance therapy prescription, deﬁned as
an unscheduled hospital admission/A&E attendance for COPD (deﬁnite
code) or lower respiratory-related events (i.e., with a lower respiratory read
code); OR lower respiratory tract infections treated with antibiotics
(deﬁnite code); OR acute use of oral steroids (deﬁnite plus possible
courses); OR antibiotics use with a lower respiratory read code within a ± 5-
day window.
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pre-existing factors such as a history of pneumonia, fracture
or Type 2 diabetes. For these patients, the risks of ICS therapy
may outweigh the potential beneﬁts. However, in patients
with comorbid asthma and COPD, an ICS and bronchodilator
combination is likely to be the most appropriate treatment,
according to guidelines. A sensitivity analysis excluding those with
potential asthma would provide an interesting perspective in a
future study.3
Conclusions
In conclusion, there is a need for prescribing to be more in line
with current GOLD and NICE guidelines, to ensure the effective
and well tolerated treatment of patients with COPD, as the clinical
reality of prescribing for patients newly diagnosed with COPD
in the UK does not reﬂect current UK4 or international3 clinical
guidelines. Our data indicate an underuse of bronchodilator
therapy and an overuse of ICS therapy in patients in GOLD group
0 20 40 60 80 100
Patients in each GOLD group (%)
LAMA+LABALABALAMA
ICS+LABA+LAMAICS+LAMAICS+LABAICS
Group D (N = 396)
Group C (N = 516)
Group B (N = 461)
Group A (N = 803)
Figure 2. Prescribing pattern for ﬁrst major therapy class within each GOLD group. GOLD, Global Initiative for Chronic Obstructive Lung
Disease; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist.
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Figure 3. Distribution of comorbidities within each GOLD group. CKD, chronic kidney disease; GERD, gastro-oesophageal reﬂux disease;
GOLD, Global Initiative for Chronic Obstructive Lung Disease.
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A and B. This would suggest that a substantial proportion of
patients with COPD may currently be undertreated while also
receiving unnecessary ICS therapy with little clinical beneﬁt and
increased risk of associated adverse events. Future research
should seek to understand the factors that determine the
selection of ﬁrst major therapy for COPD.
MATERIALS AND METHODS
This was a retrospective, observational database study. Data were
extracted from the Optimum Patient Care Research Database in September
2013. This database includes longitudinal anonymous data extracted from
353 primary care practices offering chronic respiratory services in the UK.
The database was approved by the Trent Multi Centre Research Ethics
Committee for clinical research use (approval reference 10/H0405/3).
Population for analysis
Data were extracted for patients with a ﬁrst prescription for COPD
maintenance therapy (ICS, LABA, LAMA or their combination) between
2009 and 2012 and a diagnosis of COPD at or before the date of the ﬁrst
prescription for COPD maintenance therapy. Patients were required to
have spirometry recorded within 5 years of COPD diagnosis and at least
2 years of continuous data (1 year before and 1 year after the date of the
ﬁrst prescription for COPD maintenance therapy). Patients with a diagnosis
of COPD but without sufﬁcient data to determine COPD severity
(post-bronchodilator FEV1) were excluded from the data set.
Data collection
The data collection period for the current research was from at least 1 year
before, to at least 1 year after, ﬁrst prescription for therapy, up to a
maximum of 4 years. Demographics (including age, body mass index and
smoking status), disease characteristics (including severity, therapy before
ﬁrst major COPD therapy, ﬁrst major COPD therapy, hospitalisation rate,
exacerbation rate and questionnaire, and routine modiﬁed Medical
Research Council score), comorbidities and history of pneumonia were
collected.
Analyses
Patients were stratiﬁed according to lung function-based severity (mild,
moderate, severe and very severe) and COPD group (A–D; derived from the
modiﬁed Medical Research Council score), and the demographic and
disease characteristics within each stratum were evaluated. First major
therapy class was also determined by GOLD group. History of
pneumonia and distribution of comorbidities present at or before the
initiation of ﬁrst maintenance therapy were evaluated by GOLD group. The
presence of ‘ever’ comorbidities of interest (anxiety/depression, diabetes
Type 1 and Type 2, osteoporosis, chronic kidney disease (stage 3
(moderate) to 5 (very severe)), heart failure, ischaemic heart disease,
gastro-oesophageal reﬂux disease, rhinitis and asthma (excluding those
with an asthma resolved code)) were categorised by ﬁrst major
therapy class.
Statistical analysis
Statistical analyses were descriptive throughout.
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